Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

Suprachoroidal Triamcinolone Acetonide Injection in Two Chorioretinal Diseases: One Year Results

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05337332

Enrollment

Registered

2022-04-20

Start date

2022-04-14

Completion date

2023-06-01

Last updated

2022-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy, Cystoid Macular Edema, Irvine-Gass Syndrome, Pars Planitis

Keywords

Central serous chorioretinopathy, Cystoid macular edema

Brief summary

Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.

Detailed description

Suprachoroidal triamcinolone acetonide injection is used to treat various retinal diseases, higher concentration of the injected material is found when the suprachoroidal space is used as an intraocular delivery pathway when compared to the conventional intravitreal pathway.

Interventions

DRUGTriamcinolone Acetonide

Suprachoroidal injection of triamcinolone acetonide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* patients diagnosed as central serous chorioretinopathy and patients with cystoid macular edema due to irvine-gass syndrome after cataract surgery.

Exclusion criteria

* other retinal diseases that may affect CMT and final visual outcome. * Patients with dense corneal opacity.

Design outcomes

Primary

Measure	Time frame	Description
Central macular thickness	Baseline and 12 months after injection.	Changes in central macular thickness (CMT) measured in millimeters (mm) by optical coherence tomography (OCT)

Secondary

Measure	Time frame	Description
Best corrected visual acuity	Baseline and 12 months after injection.	Changes in best corrected visual acuity (BCVA) measured in logarithm of minimal angle of resolution (LogMAR) by chart projector.

Other

Measure	Time frame	Description
Intraocular pressure	Baseline and 12 months after injection.	Changes in intraocular pressure (IOP) measured in millimeter mercury (mmHg) by applanation tonometry.

Countries

Egypt

Contacts

Primary ContactAhmed Abdelshafy, MD

ahmad4lg@gmail.com01222328766

Backup ContactMarwa Abdelshafy, MD